Stock Price & Analysis

Based on the recent data and market movements, here's a concise analysis of DOCS stock:

Technical Analysis

The stock has shown significant momentum, surging 34.06% last week and currently trading at $83.14. The RSI of 87.85 indicates overbought conditions, suggesting potential short-term pullback risks.

Fundamental Catalysts

• Strong Q3 FY2025 results with revenue growing 25% YoY to $168.6 million
• Record engagement with over 610,000 unique providers using clinical workflow tools
• AI tools grew 60% QoQ, showing strong adoption momentum
• Raised FY2025 revenue guidance to $564.6-565.6 million from previous $535-540 million

Analyst Sentiment

Recent analyst actions show mixed sentiment with price targets ranging from $55 to $90:

• Goldman Sachs: Neutral, PT $80 (from $58)
• Mizuho: Hold, PT $65 (from $55)
• Raymond James: Outperform, PT $83 (from $65)
• Leerink Partners: Upgraded to Buy, PT $90

Recommendation Given the strong fundamental momentum but overbought technical conditions, selling some positions to lock in profits while maintaining core holdings appears prudent at current levels.

Based on the provided data and recent market activity, here's the price prediction for DOCS stock in 2025:

Doximity (DOCS) stock is expected to reach $95-100 by end of 2025, driven by strong Q3 FY2025 performance with 25% revenue growth and record EBITDA margins of 60.5%. The company's AI tools grew 60% quarter-over-quarter, while its clinical workflow tools reached 610,000 unique providers.

Goldman Sachs recently raised their price target to $80 from $58, citing continued revenue momentum and strong customer additions. Multiple other analysts including Raymond James ($83) and Needham ($82) have also raised their targets following the impressive Q3 results.

The stock has already surged 36% following the Q3 earnings beat and raised FY2025 guidance to $564.6M-$565.6M from previous $535M-$540M, demonstrating strong market confidence in the company's growth trajectory and AI-driven expansion.

The S1 support level for DOCS Stock is $56.37 ,The R1 resistant level for DOCS Stock is $79.25.

As of the end of day on 2025-02-11, the price of DOCS Stock was $82.69.

The target price for DOCS Stock according to analyst rating is 66.44, with the highest price target at 90.00 and the lowest at 48.00. Analysts have a Moderate Buy rating on DOCS Stock overall.

The market cap of DOCS is $15.6B.

Based on the provided data and recent analyst reports, here's a concise analysis of DOCS' valuation:

Current Valuation Metrics:

• P/E: 53.26x (Q3 2025)
• EV/EBITDA: 38.92x
• P/S: 19.48x
• P/B: 9.71x

Recent Performance & Catalysts: The stock has seen significant momentum, surging 36% following strong Q3 results and raised FY25 guidance. The company increased its FY25 revenue guidance to $564.6M-$565.6M from previous $535M-$540M, demonstrating robust growth.

Analyst Consensus: Recent analyst actions suggest mixed views on valuation:

• Goldman Sachs raised target to $80 but maintains Hold, citing record EBITDA margins of 60.5%
• Mizuho maintains Hold with $65 target (-21.8% downside)
• Wells Fargo remains cautious with $55 target (-30.5% downside)
• Leerink Partners upgraded to Buy with $90 target (+13.7% upside)

Conclusion: At current levels ($83), DOCS appears overvalued based on traditional metrics and analyst consensus. The stock trades at premium multiples compared to healthcare IT peers, and most analysts suggest limited upside potential from current levels. While the company shows strong operational execution, the valuation appears to have priced in much of the positive momentum.

Doximity, Inc. provides a digital platform for United States (U.S) medical professionals. The Company's cloud-based platform provides tools to its members, which help them to collaborate with colleagues, coordinate patient care, conduct virtual patient visits, stay up-to-date with medical news and research, and manage careers. The Company supports physicians in practice of medicine with mobile and clinical workflow tools, such as voice and video telehealth, secure messaging and digital faxing. The Company's platform offers marketing, hiring, and telehealth solutions. Its marketing solutions enable pharmaceutical and health system customers to get content, services, and peer connections to medical professionals through a variety of modules. Its hiring solutions provide digital recruiting capabilities to health systems and medical recruiting firms. Its telehealth solutions consist of software tools that include voice and video dialers, designed to connect patients with care providers.

Based on the provided data and recent market performance, here's a price prediction for DOCS stock by 2030:

DOCS stock is projected to reach $175-185 by 2030, driven by strong revenue growth and AI-powered clinical workflow tools adoption which saw 60% quarter-over-quarter growth in Q3 2025.

The company's record-high EBITDA margin of 60.5% and successful selling seasons with large customer additions demonstrate robust business fundamentals that support long-term growth.

Multiple analysts including Goldman Sachs, Needham, and Raymond James have recently raised their price targets, with the highest target at $83, reflecting growing confidence in Doximity's expanding market position as the leading digital platform for US medical professionals.

DOCS has a total of 977 employees.